Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Single Ascending Dose Study of NPC-22 in Healthy Adult Males
NCT04203862Phase 1Completed
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Nov 2019
- Primary completion
- Feb 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of scopolamine in sialorrhea (6 arms), sponsored by Nobelpharma Co., Ltd. Primary endpoints: Adverse events, Body temperature and 6 more. Started Nov 2019; status: completed.
02
Drugs
scopolamine
03
Conditions
sialorrhea
Beyond the preview
Go deeper on NCT04203862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04203862.